Wacker Biotech US, a CDMO, and Expression Manufacturing, which specializes in viral vector technology, agreed to collaborate to advance the development and manufacturing of lentiviral-based gene and cell therapies. The goal is to offer biopharma and biotech clients with an end-to-end, optimized solution for viral vector development and production.
![Wacker Biotech US operates microbial fermentation lines with a capacity of up to 650 liters for cGMP compliant production and purification of pDNA as well as pharmaceutical proteins [WACKER]](https://www.genengnews.com/wp-content/uploads/2025/05/wacker_biotech_san_diego_wr_img_635-300x169.jpg "Wacker Biotech US operates microbial fermentation lines with a capacity of up to 650 liters for cGMP compliant production and purification of pDNA as well as pharmaceutical proteins [WACKER]")
Wacker Biotech US operates microbial fermentation lines with a capacity of up to 650 liters for cGMP compliant production and purification of pDNA as well as pharmaceutical proteins [WACKER]
Wacker Biotech has developed its PLASMITEC® platform, which utilizes a proprietary E. coli strain to enable production of (>90% supercoiled) pDNA, including transfer plasmids containing the gene of interest, as well as packaging and envelope plasmids. Wacker operates out of its pDNA center of excellence in San Diego and is supported by company sites in Europe.
Expression Manufacturing contributes its LentET
platform, which features lentiviral plasmid backbone technology and viral vector manufacturing capabilities. Company officials say Expression technology features ultra-low homology backbones to reduce recombination risks and increase safety, and optimized coding sequences for 293T cells, a widely used cell line for viral vector production, resulting in higher potency.
Expression Manufacturing operates a 43,000-ft2 viral vector manufacturing facility in West Chester, OH equipped with multiple cleanrooms, production suites, and process development rooms. [Expression Manufacturing}
“Lentiviral vectors are transforming gene therapy by enabling delivery of complex genetic payloads with unprecedented precision,” according to Bill Swaney, president, Expression Manufacturing. “Partnering with Wacker means we can combine our LentET technology with their plasmid manufacturing capabilities, offering our clients a seamless, fully integrated production pathway. This partnership not only accelerates timelines but substantially simplifies the path from research to patient delivery.”
“We are delighted to partner with Expression Manufacturing to bring end-to-end viral vector solutions to our clients,” says Mark Busch, head, business development, biopharma, Wacker Biotech US. “We [Wacker and Expression] now offer through this partnership the viral vector backbone technology to complete the manufacturing cycle for lentiviral delivery.”
The post Wacker and Expression Manufacturing Partner to Advance Lentiviral-Based Gene and Cell Therapies appeared first on GEN - Genetic Engineering and Biotechnology News.
Wacker Biotech US operates microbial fermentation lines with a capacity of up to 650 liters for cGMP compliant production and purification of pDNA as well as pharmaceutical proteins [WACKER]
Wacker Biotech has developed its PLASMITEC® platform, which utilizes a proprietary E. coli strain to enable production of (>90% supercoiled) pDNA, including transfer plasmids containing the gene of interest, as well as packaging and envelope plasmids. Wacker operates out of its pDNA center of excellence in San Diego and is supported by company sites in Europe.
Expression Manufacturing contributes its LentET
Expression Manufacturing operates a 43,000-ft2 viral vector manufacturing facility in West Chester, OH equipped with multiple cleanrooms, production suites, and process development rooms. [Expression Manufacturing}
“Lentiviral vectors are transforming gene therapy by enabling delivery of complex genetic payloads with unprecedented precision,” according to Bill Swaney, president, Expression Manufacturing. “Partnering with Wacker means we can combine our LentET technology with their plasmid manufacturing capabilities, offering our clients a seamless, fully integrated production pathway. This partnership not only accelerates timelines but substantially simplifies the path from research to patient delivery.”
“We are delighted to partner with Expression Manufacturing to bring end-to-end viral vector solutions to our clients,” says Mark Busch, head, business development, biopharma, Wacker Biotech US. “We [Wacker and Expression] now offer through this partnership the viral vector backbone technology to complete the manufacturing cycle for lentiviral delivery.”
The post Wacker and Expression Manufacturing Partner to Advance Lentiviral-Based Gene and Cell Therapies appeared first on GEN - Genetic Engineering and Biotechnology News.